Slow-onset inhibition of fumarylacetoacetate hydrolase by phosphinate mimics of the tetrahedral intermediate

Kinetics, crystal structure and pharmacokinetics

Raynard L. Bateman, Justin Ashworth, John F. Witte, L. J. Baker, Pullooru Bhanumoorthy, David E. Timm, Thomas Hurley, Markus Grompe, Ronald W. McClard

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

FAH (fumarylacetoacetate hydrolase) catalyses the final step of tyrosine catabolism to produce fumarate and acetoacetate. HT1 (hereditary tyrosinaemia type 1) results from deficiency of this enzyme. Previously, we prepared a partial mimic of the putative tetrahedral intermediate in the reaction catalysed by FAH co-crystallized with the enzyme to reveal details of the mechanism [Bateman, Bhanumoorthy, Witte, McClard, Grompe and Timm (2001) J. Biol. Chem. 276, 15284-15291]. We have now successfully synthesized complete mimics CEHPOBA {4-[(2-carboxyethyl)-hydroxyphosphinyl]-3-oxobutyrate} and COPHPAA {3-[(3-carboxy-2-oxopropyl)hydroxyphosphinyl]acrylate}, which inhibit FAH in slow-onset tight-binding mode with Ki values of 41 and 12 nM respectively. A high-resolution (1.35 Å; 1 Å = 0.1 nm) crystal structure of the FAH·CEHPOBA complex was solved to reveal the affinity determinants for these compounds and to provide further insight into the mechanism of FAH catalysis. These compounds are active in vivo, and CEHPOBA demonstrated a notable dose-dependent increase in SA (succinylacetone; a metabolite seen in patients with HT1) in mouse serum after repeated injections, and, following a single injection (1 μmol/g; intraperitoneal), only a modest regain of FAH enzyme activity was detected in liver protein isolates after 24 h. These potent inhibitors provide a means to chemically phenocopy the metabolic defects of either HT1 or FAH knockout mice and promise future pharmacological utility for hepatocyte transplantation.

Original languageEnglish
Pages (from-to)251-260
Number of pages10
JournalBiochemical Journal
Volume402
Issue number2
DOIs
StatePublished - Mar 1 2007

Fingerprint

Pharmacokinetics
Crystal structure
Tyrosinemias
Kinetics
Enzymes
Fumarates
Regain
Injections
Enzyme activity
Metabolites
Catalysis
Knockout Mice
Liver
Tyrosine
fumarylacetoacetase
Hepatocytes
Transplantation
Pharmacology
Defects
Serum

Keywords

  • Crystal structure
  • Fumarylacetoacetate
  • Hepatocyte transplantation
  • Pharmacokineties
  • Transition-state analogue
  • Tyrosinaemia

ASJC Scopus subject areas

  • Biochemistry
  • Medicine(all)

Cite this

Slow-onset inhibition of fumarylacetoacetate hydrolase by phosphinate mimics of the tetrahedral intermediate : Kinetics, crystal structure and pharmacokinetics. / Bateman, Raynard L.; Ashworth, Justin; Witte, John F.; Baker, L. J.; Bhanumoorthy, Pullooru; Timm, David E.; Hurley, Thomas; Grompe, Markus; McClard, Ronald W.

In: Biochemical Journal, Vol. 402, No. 2, 01.03.2007, p. 251-260.

Research output: Contribution to journalArticle

Bateman, Raynard L. ; Ashworth, Justin ; Witte, John F. ; Baker, L. J. ; Bhanumoorthy, Pullooru ; Timm, David E. ; Hurley, Thomas ; Grompe, Markus ; McClard, Ronald W. / Slow-onset inhibition of fumarylacetoacetate hydrolase by phosphinate mimics of the tetrahedral intermediate : Kinetics, crystal structure and pharmacokinetics. In: Biochemical Journal. 2007 ; Vol. 402, No. 2. pp. 251-260.
@article{3d1e713aae534ac5941b6a58f98b809f,
title = "Slow-onset inhibition of fumarylacetoacetate hydrolase by phosphinate mimics of the tetrahedral intermediate: Kinetics, crystal structure and pharmacokinetics",
abstract = "FAH (fumarylacetoacetate hydrolase) catalyses the final step of tyrosine catabolism to produce fumarate and acetoacetate. HT1 (hereditary tyrosinaemia type 1) results from deficiency of this enzyme. Previously, we prepared a partial mimic of the putative tetrahedral intermediate in the reaction catalysed by FAH co-crystallized with the enzyme to reveal details of the mechanism [Bateman, Bhanumoorthy, Witte, McClard, Grompe and Timm (2001) J. Biol. Chem. 276, 15284-15291]. We have now successfully synthesized complete mimics CEHPOBA {4-[(2-carboxyethyl)-hydroxyphosphinyl]-3-oxobutyrate} and COPHPAA {3-[(3-carboxy-2-oxopropyl)hydroxyphosphinyl]acrylate}, which inhibit FAH in slow-onset tight-binding mode with Ki values of 41 and 12 nM respectively. A high-resolution (1.35 {\AA}; 1 {\AA} = 0.1 nm) crystal structure of the FAH·CEHPOBA complex was solved to reveal the affinity determinants for these compounds and to provide further insight into the mechanism of FAH catalysis. These compounds are active in vivo, and CEHPOBA demonstrated a notable dose-dependent increase in SA (succinylacetone; a metabolite seen in patients with HT1) in mouse serum after repeated injections, and, following a single injection (1 μmol/g; intraperitoneal), only a modest regain of FAH enzyme activity was detected in liver protein isolates after 24 h. These potent inhibitors provide a means to chemically phenocopy the metabolic defects of either HT1 or FAH knockout mice and promise future pharmacological utility for hepatocyte transplantation.",
keywords = "Crystal structure, Fumarylacetoacetate, Hepatocyte transplantation, Pharmacokineties, Transition-state analogue, Tyrosinaemia",
author = "Bateman, {Raynard L.} and Justin Ashworth and Witte, {John F.} and Baker, {L. J.} and Pullooru Bhanumoorthy and Timm, {David E.} and Thomas Hurley and Markus Grompe and McClard, {Ronald W.}",
year = "2007",
month = "3",
day = "1",
doi = "10.1042/BJ20060961",
language = "English",
volume = "402",
pages = "251--260",
journal = "Biochemical Journal",
issn = "0264-6021",
publisher = "Portland Press Ltd.",
number = "2",

}

TY - JOUR

T1 - Slow-onset inhibition of fumarylacetoacetate hydrolase by phosphinate mimics of the tetrahedral intermediate

T2 - Kinetics, crystal structure and pharmacokinetics

AU - Bateman, Raynard L.

AU - Ashworth, Justin

AU - Witte, John F.

AU - Baker, L. J.

AU - Bhanumoorthy, Pullooru

AU - Timm, David E.

AU - Hurley, Thomas

AU - Grompe, Markus

AU - McClard, Ronald W.

PY - 2007/3/1

Y1 - 2007/3/1

N2 - FAH (fumarylacetoacetate hydrolase) catalyses the final step of tyrosine catabolism to produce fumarate and acetoacetate. HT1 (hereditary tyrosinaemia type 1) results from deficiency of this enzyme. Previously, we prepared a partial mimic of the putative tetrahedral intermediate in the reaction catalysed by FAH co-crystallized with the enzyme to reveal details of the mechanism [Bateman, Bhanumoorthy, Witte, McClard, Grompe and Timm (2001) J. Biol. Chem. 276, 15284-15291]. We have now successfully synthesized complete mimics CEHPOBA {4-[(2-carboxyethyl)-hydroxyphosphinyl]-3-oxobutyrate} and COPHPAA {3-[(3-carboxy-2-oxopropyl)hydroxyphosphinyl]acrylate}, which inhibit FAH in slow-onset tight-binding mode with Ki values of 41 and 12 nM respectively. A high-resolution (1.35 Å; 1 Å = 0.1 nm) crystal structure of the FAH·CEHPOBA complex was solved to reveal the affinity determinants for these compounds and to provide further insight into the mechanism of FAH catalysis. These compounds are active in vivo, and CEHPOBA demonstrated a notable dose-dependent increase in SA (succinylacetone; a metabolite seen in patients with HT1) in mouse serum after repeated injections, and, following a single injection (1 μmol/g; intraperitoneal), only a modest regain of FAH enzyme activity was detected in liver protein isolates after 24 h. These potent inhibitors provide a means to chemically phenocopy the metabolic defects of either HT1 or FAH knockout mice and promise future pharmacological utility for hepatocyte transplantation.

AB - FAH (fumarylacetoacetate hydrolase) catalyses the final step of tyrosine catabolism to produce fumarate and acetoacetate. HT1 (hereditary tyrosinaemia type 1) results from deficiency of this enzyme. Previously, we prepared a partial mimic of the putative tetrahedral intermediate in the reaction catalysed by FAH co-crystallized with the enzyme to reveal details of the mechanism [Bateman, Bhanumoorthy, Witte, McClard, Grompe and Timm (2001) J. Biol. Chem. 276, 15284-15291]. We have now successfully synthesized complete mimics CEHPOBA {4-[(2-carboxyethyl)-hydroxyphosphinyl]-3-oxobutyrate} and COPHPAA {3-[(3-carboxy-2-oxopropyl)hydroxyphosphinyl]acrylate}, which inhibit FAH in slow-onset tight-binding mode with Ki values of 41 and 12 nM respectively. A high-resolution (1.35 Å; 1 Å = 0.1 nm) crystal structure of the FAH·CEHPOBA complex was solved to reveal the affinity determinants for these compounds and to provide further insight into the mechanism of FAH catalysis. These compounds are active in vivo, and CEHPOBA demonstrated a notable dose-dependent increase in SA (succinylacetone; a metabolite seen in patients with HT1) in mouse serum after repeated injections, and, following a single injection (1 μmol/g; intraperitoneal), only a modest regain of FAH enzyme activity was detected in liver protein isolates after 24 h. These potent inhibitors provide a means to chemically phenocopy the metabolic defects of either HT1 or FAH knockout mice and promise future pharmacological utility for hepatocyte transplantation.

KW - Crystal structure

KW - Fumarylacetoacetate

KW - Hepatocyte transplantation

KW - Pharmacokineties

KW - Transition-state analogue

KW - Tyrosinaemia

UR - http://www.scopus.com/inward/record.url?scp=33847726934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847726934&partnerID=8YFLogxK

U2 - 10.1042/BJ20060961

DO - 10.1042/BJ20060961

M3 - Article

VL - 402

SP - 251

EP - 260

JO - Biochemical Journal

JF - Biochemical Journal

SN - 0264-6021

IS - 2

ER -